Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
30 Maggio 2023 - 3:00PM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
its entry into a research agreement expanding the study of its
novel joint homing peptides targeting rheumatoid arthritis (RA),
designated as SPU-21, in human synovial tissue surrounding joints
and tendons.
Eric Weisblum, Chief Executive Officer of Silo Pharma, stated,
“The initial three-month pilot study of SPU-21 assessed the peptide
in healthy human and RA synovial tissue. The next step is to
further investigate cyclic peptides in human tissue assays for
optimization and binding affinity.”
Silo Pharma is advancing the development of SPU-21 liposomal
joint homing peptides in collaboration with the University of
Maryland, Baltimore (UMB).
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information visit
www.silopharma.com
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company under takes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact
800-705-0120 investors@silopharma.com
Grafico Azioni Silo Pharma (NASDAQ:SILO)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Silo Pharma (NASDAQ:SILO)
Storico
Da Set 2023 a Set 2024